Across these stories, you’ll see how our teams move from mechanism to medicine: leveraging resources such as Mount Sinai’s diverse BioMe biobank and a clinical research engine that has supported 50+ clinical trials, including first-in-human studies and emerging therapeutic approaches.
In this report: neurogenomics, rare disease trials, AI-enabled precision medicine, immunogenomics and interception strategies, microbiome-driven discovery, and new approaches to diagnosis and therapy for rare and metabolic disorders.